JPH0428720B2 - - Google Patents
Info
- Publication number
- JPH0428720B2 JPH0428720B2 JP57151754A JP15175482A JPH0428720B2 JP H0428720 B2 JPH0428720 B2 JP H0428720B2 JP 57151754 A JP57151754 A JP 57151754A JP 15175482 A JP15175482 A JP 15175482A JP H0428720 B2 JPH0428720 B2 JP H0428720B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- fragment
- ncs
- neocarzinostatin
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims description 50
- 102000018358 immunoglobulin Human genes 0.000 claims description 50
- 239000012634 fragment Substances 0.000 claims description 38
- 229950009268 zinostatin Drugs 0.000 claims description 31
- 101710204212 Neocarzinostatin Proteins 0.000 claims description 29
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 claims description 29
- 230000000259 anti-tumor effect Effects 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 14
- 230000022534 cell killing Effects 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 11
- 125000004434 sulfur atom Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 6
- 125000000962 organic group Chemical group 0.000 claims description 6
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims description 5
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000003431 cross linking reagent Substances 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- -1 dimethylene group Chemical group 0.000 description 14
- 239000000047 product Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N βâMercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- 102100035695 Gamma-aminobutyric acid receptor-associated protein Human genes 0.000 description 5
- 101001001372 Homo sapiens Gamma-aminobutyric acid receptor-associated protein Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 125000002228 disulfide group Chemical group 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 125000003158 alcohol group Chemical group 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000007093 Leukemia L1210 Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex⢠Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108020001775 protein parts Proteins 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- TUFZOTRONDWKTG-SSDOTTSWSA-N (2R)-2-anilino-3,3-dinitro-3-sulfanylpropanoic acid Chemical compound [N+](=O)([O-])C([C@H](NC1=CC=CC=C1)C(=O)O)(S)[N+](=O)[O-] TUFZOTRONDWKTG-SSDOTTSWSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- SJUPVMFZNVNLSE-UHFFFAOYSA-N ON1C(CCC1=O)=O.C(C1=CC=CC=C1)(=O)O Chemical compound ON1C(CCC1=O)=O.C(C1=CC=CC=C1)(=O)O SJUPVMFZNVNLSE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000186991 Streptomyces carzinostaticus Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
æ¬çºæã¯æ°èŠãªéžæç殺现èæ§èçœè€åäœãšã
ã®è£œé æ¹æ³ã«é¢ãããæŽã«è©³ããã¯ãæè
«çIgG
å
ç«ã°ãããªã³ããããã¯ãã®æåçµåéšäœãå«
ããã©ã°ã¡ã³ããããªãæ§æéšåãšãæçå€ããª
ã«ã«ããã¹ã¿ãã³ãããªãæ§æéšåãæãããæ°
èŠãªéžæç殺现èæ§èçœè€åäœãšãã®è£œé æ¹æ³ã«
é¢ãããã®ã§ããã
ããçš®ã®çŽ°èã ããéžæçã«æ®ºãããšãç®çãš
ããŠããã®æšç现èãšéžæçã«çµåãããå
ç«ã°
ãããªã³ãçš®ã
ã®æçå€ãšçµåãããè©Šã¿ããªã
ããŠããïŒäŸãã°ãã〠ãŽãŒã¹ïŒT.GhoseïŒ
ãããžã€ãŒãã« ãªã 㶠ãã·ãšãã«ãã€ã³ãµ
㌠ã€ã³ã¹ãã€ãã³ãŒãïŒJ.Natl.Cancer Inst.ïŒïŒ
第61å·»ã第657ã676é ïŒ1978幎åç
§ïŒãããªã«ã«
ããã¹ã¿ãã³ã¯ããã®çŽ°èæ¯æ§ã匷ããæ
ã«ãã
ããç®çã«äœ¿çšããæçå€ãšããŠé©ããŠããããš
ãèããããå
ç«ã°ãããªã³ãšã®è€åäœãæ€èšã
ãããäŸãã°æšæãã¯ïŒâãšãã«âïŒâïŒïŒâãž
ã¡ãã«ã¢ãããããã«ïŒã«ã«ããžã€ããïŒä»¥äž
WSCIãšããïŒãè±æ°Žçž®åå€ãšããŠçšããŠãå
ç«
ã°ãããªã³ãšããªã«ã«ããã¹ã¿ãã³ãçµåãã
ããåŸãããè€åäœã¯ããªã«ã«ããã¹ã¿ãã³æŽ»æ§
ãšãšãã«æäœæŽ»æ§ãä¿æããŠããããšãåã³ããª
ã«ã«ããã¹ã¿ãã³åç¬ããæå¹ã«æšç现èã®
DNAåæãé»å®³ãããšå ±åããŠããïŒçãšååŠ
çæ³ã第ïŒå·»èšæå¢åïŒ75ã81é 1979幎å
ç
§ïŒããŸãããž ãŠã³ã°ïŒG.JungïŒãã¯ãå
ç«ã°
ãããªã³ãšããªã«ã«ããã¹ã¿ãã³ã«æ¶æ©å€ãçšã
ãŠå°å
¥ããç¡«é»ååéã«ãžã¹ã«ãã€ãçµåã圢æ
ããããããšã«ããè€åäœãäœè£œãããã®è€åäœ
ã¯ããªã«ã«ããã¹ã¿ãã³æŽ»æ§ãä¿æããŠãããšå ±
åããŠããïŒãã€ãªã±ãã«ã« ã¢ã³ã ãã€ãªã
ã€ãžã«ã« ãªãµãŒã ã³ããŠãã€ã±ãŒã·ãšã³ãº
ïŒBiochemical and Biophysical Reserch
ComunicationsïŒïŒç¬¬101å·»ïŒ599ã606é ïŒ1981幎
åç
§ïŒãããããªãããè€åäœäœè£œã«åœãWSCI
ãçž®åå€ãšããŠçšããæ¹æ³ã¯ãWSCIã¯ã¢ããåº
ãšã«ã«ããã·ã«åºéã§è±æ°Žçž®åãèµ·ããããã¢ã
ãçµåã圢æãããè©Šè¬ã§ãããå
ç«ã°ãããªã³
ãšããªã«ã«ããã¹ã¿ãã³éã®æ¶æ©ã®ä»ã«ãäžã€ã®
ååå
ã§ã®æ¶æ©ããå
ç«ã°ãããªã³åå¿ã®æ¶æ©ã
ããã¯ããªã«ã«ããã¹ã¿ãã³åå¿ã®æ¶æ©ãèµ·ã
ããæãŸããçæç©ã¯åŸã«ããããŸããå
ç«ã°ã
ããªã³åã³ããªã«ã«ããã¹ã¿ãã³ã«ã¯è€æ°åã®ã¢
ããåºåã³ã«ã«ããã·ã«åºãããããã«ãå
ç«ã°
ãããªã³ãšããªã«ã«ããã¹ã¿ãã³ãè€æ°åäºãã«
çµåããé«ååç©è³ªãçžåœçšåºŠçæããWSCIã
çšããæ¶æ©æ¹æ³ã«ãã€ãŠã¯å®éã«æ²»çã«äŸãåŸã
è€åäœãåŸãããšã¯æ¥µããŠå°é£ã§ããããŸããäž
èšã®ãŠã³ã°ãã®è€åäœã§ã¯ãå
ç«ã°ãããªã³ãšã
ãªã«ã«ããã¹ã¿ãã³ããžã¹ã«ãã€ãïŒââ
âïŒçµåã«ããçµåãããŠããŠããããé倩ç¶ã®
ãžã¹ã«ãã€ãçµåã¯ãã®çžåœéšåã¯è¡æ¶²äžã§åæ
ãããã®ã§ããããè€åäœã¯æšç现èã«å°éãã
åã«ãã®è¬å¹ãäœäžãããšããæ¬ ç¹ãããã
æ¬çºæè
ãã¯ãå
è¡æè¡ã®æãããããæ¬ ç¹ã
解æ¶ããäŸãã°ãç现èã®åŠã殺ãã¹ã现èã«éž
æçã«åŒ·åãªæ¯æ§ãçºæ®ããéžæç殺现èæ§èçœ
è€åäœãéçºãã¹ãéæç 究ã®çµæãæ¬çºæå°é
ããã
å³ã¡ãæ¬çºæã¯ãæè
«çIgGå
ç«ã°ãããªã³ãŸ
ãã¯ãã®ãã©ã°ã¡ã³ããšããªã«ã«ããã¹ã¿ãã³
ããçµåãããŠãªãäžèšåŒãã
ãåŒäžãAbã¯æè
«çIgGå
ç«ã°ãããªã³ãŸã
ã¯ãã®ãã©ã°ã¡ã³ããè¡šããAbã¯ãã®ååŠæ§é
äžã®ã¢ããåºã§çµåããŠãããNCSã¯ããªã«ã«
ããã¹ã¿ãã³ãè¡šããNCSã¯ãã®ååŠæ§é äžã®
ã¢ããåºã§çµåããŠãããã¯ïœâããšãã¬ã³åº
ãŸãã¯ããªã¡ãã¬ã³åºããïœã¯ïŒãŸãã¯ïŒãè¡š
ããã¯ã€ãªãŠååãè¡šãããïœãïŒã®ãšãã¯
æè
«çIgGå
ç«ã°ãããªã³ãŸãã¯ãã®ãã©ã°ã¡ã³
ãã®ååŠæ§é ãå
æ¥æããããªãŒã«åºã«ç±æ¥ãã
ïœãïŒã®ãšãã¯å°å
¥ãããææ©åºãå«æããããª
ãŒã«åºã«ç±æ¥ãããïœã¯ïŒãïŒã®æŽæ°ãè¡šããã
ã§è¡šãããéžæç殺现èæ§èçœè€åäœã§ããã
æ¬çºæã«ãããŠå
ç«ã°ãããªã³ãšã¯ãç Žå£ãã¹
ãæšç现èãèªèããæäœãŸãã¯ãããæäœãå«
ãã°ãããªã³ãèšãããããå
ç«ã°ãããªã³ã¯ã
æšç现èãç现èã®å Žåã«ã¯æè
«çå
ç«ã°ãããª
ã³ãšåŒã°ãããæè
«çå
ç«ã°ãããªã³ã«ã¯ãäŸã
ã°çæ£è
ã®è¡æž
ããããŸãã¯è
«ç现èåã¯è
«çç¹
ç°æåæãã¯è
«çé¢é£æåããµã«ããŠãããŠã·ã
ã€ã®ããããžããŠãµã®çã®åç©ã«éå
ç«ããè¡æž
ãããã³ãŒã³ã®ãšã¿ããŒã«åç»æ³ãç¡«å®åç»æ³ã
ã€ãªã³äº€æã¯ãããã°ã©ãã€ãŒæ³çã®å
¬ç¥ã®æ段
ã«ãã€ãŠèª¿è£œãããããã«å¿
èŠã«ãã€ãŠã¯å皮现
èãçšããŠåžåãåžçæäœãã»ã©ãããŠåŸãããš
ãã§ãããšããã®æäœæŽ»æ§ãæããèçœè³ªïŒå
ç«
ã°ãããªã³ïŒããããã¯ãç现èãçæåãåç©
ã«å
ç«ããŠåŸãæäœç£çæ§ãªã³ãçããäŸãã°éªš
é«è
«ç现èãšèåãããŠãå¹é€å¯èœã§æäœãç£ç
ããèå现èïŒãã€ããªããŒãïŒãåŸããããin
vitvoïŒçäœå€ïŒã§å¹é€ããããæãã¯åç©ã«ç§»æ€
ããŠin vivoïŒçäœå
ïŒã§å¹æ®ããããŠããã®å¹é€
液ãŸãã¯è¡æž
ãè
¹è
液ãã調補ããã極ããŠç¹ç°
æ§ã®é«ãæäœæŽ»æ§ãæããå
ç«ã°ãããªã³ãå«ãŸ
ããããŸããè
«ççµç¹ããçé¢æŽ»æ§å€çã®å€æ§å€
ã§æè
«çæäœãéé¢ãããããããåè¿°ãšåæ§ãª
æ段ã§èª¿è£œãããæäœæŽ»æ§ãæããå
ç«ã°ãããª
ã³ãæ¬çºæã®å
ç«ã°ãããªã³ã«å«ãŸããã
å
ç«ã°ãããªã³ã«ã¯IgGïŒIgAïŒIgMïŒIgDïŒ
IgEã®ïŒã€ã®ã¯ã©ã¹ãããããšãç¥ãããŠãã
ãããã®åºæ¬æ§é ã¯ã第ïŒå³ã«æš¡åŒçã«ç€ºããåŠ
ããå³äžïŒ¬ã§ç€ºãããéïŒæ¬ãšïŒšã§ç€ºããã
éïŒæ¬ãå°ãªããšãïŒã€ã®ãžã¹ã«ãã€ãçµåïŒâ
ââçµåïŒã§çµã°ãããã®ã§ããç¹ããŸãã
第äžå³ã«ç€ºããåŠããæåçµå掻æ§ããã€Fabéš
åãšãšããšã¯ã¿ãŒæŽ»æ§ããã€Fcéšåããæãç¹
ã«ãããŠäžèŽããŠãããæ¬çºæã§çšããå
ç«ã°ã
ããªã³ã¯äžèšã®ïŒã€ã®ã¯ã©ã¹ã®ãã¡IgGã¯ã©ã¹ã®
å
ç«ã°ãããªã³ã§ããã
æ¬çºæã®éžæç殺现èæ§èçœè€åäœã®äžæ¹ã®æ§
æéšåãšããŠæè
«çIgGå
ç«ã°ãããªã³ãŸãã¯ã
ã®ãã©ã°ã¡ã³ããçšããããããæè
«çIgGå
ç«
ã°ãããªã³ã®ãã©ã°ã¡ã³ããšããŠã¯ãåè¿°ã®ããš
ãå
ç«ã°ãããªã³ã®æäœæŽ»æ§ãæããéšäœãå«ã
ãã©ã°ã¡ã³ããçšãããããããããã©ã°ã¡ã³ã
ãšããŠã¯ãç¹ã«FabïŒFabâ²ïŒFabéšãšããããã
ã³ãžéšïŒç¬¬ïŒå³ãã«æç·ã§ç€ºããéšåïŒãšãããª
ãéšåïŒåã³Fabâ²ã®ïŒéäœã§ããïŒabïŒâ²2ãæ
ãŸããã
æ¬çºæã«ãããŠçšããããããªã«ã«ããã¹ã¿ã
ã³ã¯ãStreptomyces Carzinostaticusã®å¹é€
液ããåŸãããååéçŽ11000ã®æ¥æ§çœè¡ç
ãè
çãèè±çãèèççã«æè
«ç掻æ§ã瀺ãèçœæ§
æçç©è³ªã§ãããååäžã«ïŒåã®éé¢ã¢ããåºã
æããŠããããŸããããªã«ã«ããã¹ã¿ãã³ã«ã¯é
èçœéšåãå³ã¡ã¯ãã¢ããªã¢ãäŸåãããã®ã¯ã
ã¢ããªã¢ãããªã«ã«ããã¹ã¿ãã³ã®çç©æŽ»æ§ãæ
ããèçœéšåã¯ã¯ãã¢ããªã¢ã®å®å®åãéæ¬ã掻
æ§åçã«é¢äžããŠããããšãæããã«ãããŠãã
ïŒæ±æžãç³ç°ãå»åŠã®ããã¿ã第120å·»ã79ã80
é ã1982幎åç
§ïŒããããååæ§é çç¹åŸŽãæ¬çº
æã«ãããŠã¯æå©ã«çšããããã
äžèšåŒããã«ãããŠïœïŒïŒã®å Žåã«ã¯ãã¯å
ç«ã°ãããªã³ãŸãã¯ãã®ãã©ã°ã¡ã³ãã«ç±æ¥ãã
ç¡«é»ååã§ãããïœïŒïŒã®å Žåã«ã¯æ¶æ©å€ã«ãã
å°å
¥ãããç¡«é»ååã§ãããåŒããã«ãããŠã
ãžã¡ãã¬ã³åºã¯äŸãã°äžèšåŒãã
ãåŒäžãã¯çµåããŠããç¡«é»ååãšå
±ã«æŽ»
æ§ãžã¹ã«ãã€ãåºã圢æãåŸãïŒäŸ¡ã®ææ©åºãã
X3ã¯ãžã¡ãã¬ã³åºããã¯æŽ»æ§ãšã¹ãã«ã®ã¢ã«
ã³ãŒã«æ®åºãè¡šãããã
ã§è¡šããããæ¶æ©å€ã«ç±æ¥ããã
ã§è¡šãããããçµåããŠããç¡«é»ååãšå
±ã«
掻æ§ãžã¹ã«ãã€ãåºã圢æãåŸãïŒäŸ¡ã®ææ©åºã®
å
·äœäŸãšããŠã¯ãïŒâããªãžã«ããªåº
The present invention relates to a novel selective cell-killing protein complex and a method for producing the same. For more information, see Antitumor IgG
The present invention relates to a novel selective cell-killing protein complex having a component consisting of an immunoglobulin or a fragment thereof containing an antigen-binding site and a component consisting of the anticancer drug neocarzinostatin, and a method for producing the same. For the purpose of selectively killing only certain types of cells, attempts have been made to combine various anticancer drugs with immunoglobulins that can selectively bind to the target cells (for example, T. Ghose).
et al., Journal of the National Cancer Inst.
61, pp. 657-676, 1978). Neocarzinostatin is considered to be suitable as an anticancer agent for such purposes because of its strong cytotoxicity, and a complex with immunoglobulin was investigated. For example, Kimura et al.
WSCI) was used as a dehydration condensation agent to bind immunoglobulin and neocarzinostatin, and the resulting complex possessed antibody activity as well as neocarzinostatin activity, and was found to be more effective than neocarzinostatin alone. effectively target cells
It has been reported that it inhibited DNA synthesis (see Cancer and Chemotherapy, Vol. 6 Extra Edition, pp. 75-81, 1979). In addition, G. Jung et al. created a complex by forming a disulfide bond between the sulfur atoms introduced into immunoglobulin and neocarzinostatin using a cross-linking agent, and the complex was developed into neocarzinostatin. It has been reported that nostatin activity was maintained (Biochemical and Biophysical Research Co., Ltd.).
101, pp. 599-606, 1981). However, when preparing the complex, WSCI
In the method of using WSCI as a condensing agent, WSCI is a reagent that causes dehydration condensation between an amino group and a carboxyl group to form an amide bond. Cross-linking between immunoglobulins, cross-linking between neocarzinostatins, and cross-linking between neocarzinostatins also occur, making it difficult to obtain desired products. In addition, since immunoglobulin and neocarzinostatin have multiple amino groups and carboxyl groups, a considerable amount of polymeric substances in which multiple immunoglobulins and neocarzinostatin are bonded to each other is produced, and cross-linking using WSCI is required. Depending on the method, it is extremely difficult to obtain a complex that can actually be used for treatment. In addition, in the above-mentioned complex of Jung et al., immunoglobulin and neocarzinostatin are disulfide (-S-S
-) bonds, and since a significant portion of such unnatural disulfide bonds are cleaved in the blood, such complexes have the disadvantage that their efficacy is reduced before they reach the target cells. The present inventors have conducted extensive research in order to overcome these drawbacks of the prior art and develop a selective cell-killing protein complex that selectively exhibits strong toxicity to cells to be killed, such as cancer cells. As a result, the present invention was achieved. That is, the present invention provides the following formula [] which is obtained by binding an anti-tumor IgG immunoglobulin or a fragment thereof to neocarzinostatin. [wherein Ab represents an antitumor IgG immunoglobulin or a fragment thereof, and Ab is bonded through an amino group in its chemical structure. NCS stands for neocarzinostatin, and NCS is attached through an amino group in its chemical structure. X represents an m-phenylene group or a trimethylene group, and m represents 0 or 1. S represents a sulfur atom, and when m is 0, S is derived from a thiol group originally contained in the chemical structure of the antitumor IgG immunoglobulin or its fragment;
When m is 1, it originates from a thiol group contained in the introduced organic group. n represents an integer of 1 to 5. ] It is a selective cell-killing protein complex represented by In the present invention, immunoglobulin refers to an antibody that recognizes a target cell to be destroyed or a globulin containing such an antibody. Such immunoglobulin is
When the target cell is a cancer cell, it is called an antitumor immunoglobulin. Anti-tumor immunoglobulins can be obtained, for example, from the serum of cancer patients, or from tumor cells or tumor-specific or tumor-associated antigens from monkeys, horses, cows, etc.
Cohn's ethanol fractionation method, ammonium sulfate fractionation method,
Proteins with antibody activity (immunoglobulins) that can be prepared by known means such as ion-exchange chromatography and, if necessary, subjected to absorption and adsorption operations using various cells. Alternatively, antibody-producing lymphocytes obtained by immunizing an animal with cancer cells or cancer antigens are fused with, for example, bone marrow tumor cells to obtain culturable antibody-producing fusion cells (hybridomas), which are then inoculated into
An immune system with highly specific antibody activity that is prepared from culture fluid, serum, or peritoneal fluid after being cultured in vitro (externally) or transplanted into animals and cultured in vivo (in vivo). Contains globulin. Furthermore, the immunoglobulin of the present invention also includes an immunoglobulin having antibody activity that is prepared by releasing anti-tumor antibodies from tumor tissue using a denaturing agent such as a surfactant, and then preparing the anti-tumor antibody therefrom by the same means as described above. Immunoglobulins include IgG, IgA, IgM, IgD,
It is known that there are five classes of IgE, and their basic structure, as schematically shown in Figure 1, consists of two L chains, indicated by L, and an H chain, indicated by H.
Two chains have at least three disulfide bonds (-
S-S-bond), and
As shown in Figure 1, they are identical in that they consist of a Fab portion with antigen-binding activity and an Fc portion with effector activity. The immunoglobulin used in the present invention is an IgG class immunoglobulin among the above five classes. Anti-tumor IgG immunoglobulin or a fragment thereof is used as one component of the selective cell-killing protein complex of the present invention, and the fragment of anti-tumor IgG immunoglobulin has the antibody activity of the above-mentioned immunoglobulin. A fragment containing the site is used. Such fragments include, in particular, Fab, Fab' (a portion consisting of a Fab part and a so-called hinge part (the shaded part in Figure 1B)), and F(ab)' 2 , which is a dimer of Fab'. desirable. Neocarzinostatin used in the present invention is a protein antibiotic with a molecular weight of approximately 11,000 obtained from the culture solution of Streptomyces Carzinostaticus that exhibits antitumor activity against acute leukemia, gastric cancer, bladder cancer, liver cancer, etc. It has two free amino groups. In addition, neocarzinostatin is dependent on a non-protein part, that is, a chromophore, and this chromophore is responsible for the biological activity of neocarzinostatin, and the protein part is involved in the stabilization, transport, activation, etc. of the chromophore. (Edo, Ishida, History of Medicine, Vol. 120, 79-80)
1982), such molecular structural features are advantageously used in the present invention. In the above formula [], when m=0, S is a sulfur atom derived from an immunoglobulin or a fragment thereof, and when m=1, it is a sulfur atom introduced by a crosslinking agent. In the formula [],
For example, the dimethylene group has the following formula [] [In the formula, Y is a monovalent organic group that can form an active disulfide group together with the bonded sulfur atom S,
X 3 represents a dimethylene group, and Z represents an alcohol residue of an active ester. ] Derived from the crosslinking agent represented by Specific examples of the monovalent organic group represented by Y that can form an active disulfide group together with the bonded sulfur atom include 2-pyridylthio group.
ãåŒãïŒâããªãžã«ããªåº[Formula] 4-pyridylthio group
ãåŒãïŒâã«ã«ããã·âïŒâãã ãããšãã«ããªåº[Formula] 3-carboxy-4-nito lophenylthio group
ãåŒãïŒâ
ã«ã«ããã·âïŒâããªãžã«ãžããªåº
[Formula] 4-carboxy-2-pyridyldithio group
ãåŒãâãªãã·âïŒâã ãªãžã«ãžããª[Formula] N-oxy-2-pi lysyldithio
ãåŒãïŒâãããããš ãã«ããªåº[Formula] 2-nitrophe Nylthio group
ãåŒãïŒâãããâïŒâ ããªãžã«ããªåº[Formula] 4-nitro-2- Pyridylthio group
ãåŒãïŒâã ã³ãŸãã¢ãŸã€ã«ããªåº[Formula] 2-be nzothiazoylthio group
ãåŒã
ïŒâãã³ãŸã€ãããŸã€ã«ããªåº
[Formula] 2-benzimidazoylthio group
ãåŒãâããšãã«ã¢ããâ Nâ²âããšãã«ã€ããã¡ãã«ããªåº[Formula] N-phenylamino- Nâ²-phenyliminomethylthio group
ãåŒãçãæããããšãã§
ãããã§è¡šãããã掻æ§ãšã¹ãã«ã®ã¢ã«ã³ãŒã«
æ®åºã®å
·äœäŸãšããŠã¯ïŒ®âãµã¯ã·ã³ã€ãããã·åº
[Formula] etc. can be mentioned. A specific example of the alcohol residue of the active ester represented by Z is an N-succinimidoxy group.
ãåŒãâããããã·âïŒâãã«ã
ã«ãã³âïŒïŒïŒâãžã«ã«ããžã€ãããã·åº
[Formula] N-hydroxy-5-norbornene-2,3-dicarbodiimidoxy group
ãåŒãâãã¿ã«ã€ãããã· åº[Formula] N-phthalimidoxy base
ãåŒãïœâãããããšãã
ã·åºïŒïŒïŒïŒâãžãããããšããã·åºïŒïŒïŒïŒïŒ
ïŒâããªã¯ããããšããã·åºïŒãã³ã¿ã¯ããããš
ããã·åºçãæããããšãã§ãããã§è¡šããã
ãã€ãããšã¹ãã«ã®ã¢ã«ã³ãŒã«æ®åºã®å
·äœäŸãšã
ãŠã¯ã¡ããã·ïŒãšããã·åºçãæããããšãã§ã
ããã§è¡šããããããã²ã³ååã®å
·äœäŸãšããŠ
ã¯ãå¡©çŽ ãèçŽ ããšãŠçŽ çãæããããšãã§ã
ããäžèšåŒããäžã®ïŒžã¯äžèšåŒãã
ãåŒäžãX4ã¯ïœâããšãã¬ã³åºãŸãã¯ããªã¡
ãã¬ã³åºãè¡šãããã®å®çŸ©ã¯åŒãããšåããã
ã§è¡šããããæ¶æ©å€ã®X4ã«ç±æ¥ãããã§è¡šã
ããã掻æ§ãšã¹ãã«ã®ã¢ã«ã³ãŒã«æ®åºã®å
·äœäŸãš
ããŠã¯ãäžèšã®åŒããã®å Žåãšåãã§ãããæ¶
æ©å€ã®å
·äœäŸãšããŠã¯ãåŒããã§è¡šããããæ¶
æ©å€ãšããŠãâãµã¯ã·ã³ã€ããžã«ïŒâïŒïŒâã
ãªãžã«ãžããªïŒããããªããŒãããåŒããã§è¡š
ããããæ¶æ©å€ãšããŠãã¡ã¿ãã¬ã€ããå®æ¯éŠé
ž
âããããã·ãµã¯ã·ã³ã€ãããšã¹ãã«ããã¬ã€
ããé
¢é
žïŒïŒïŒâãžãããããšããŒã«ãšã¹ãã«ã
æããããšãã§ããã
æ¬çºæã®éžæç殺现èæ§èçœè€åäœã¯ãæè
«ç
IgGå
ç«ã°ãããªã³ãŸãã¯ãã®ãã©ã°ã¡ã³ãã«ã
ãªãŒã«åºãçºçããããå°å
¥ããŠäžèšåŒãã
ãåŒäžãAbã¯æè
«çIgGå
ç«ã°ãããªã³ãŸã
ã¯ãã®ãã©ã°ã¡ã³ããè¡šããAbã¯ãã®ååŠæ§é
äžã®ã¢ããåºã§çµåããŠãããïœã¯ïŒãŸãã¯ïŒã
è¡šããã¯ã€ãªãŠååãè¡šãããïœãïŒã®ãšã
ã¯æè
«çIgGå
ç«ã°ãããªã³ãŸãã¯ãã®ãã©ã°ã¡
ã³ãã®ååŠæ§é ãå
æ¥æããããªãŒã«åºã«ç±æ¥
ããïœãïŒã®ãšãã¯å°å
¥ãããææ©åºãå«æãã
ããªãŒã«åºã«ç±æ¥ãããn1ã¯ïŒãïŒã®æŽæ°ãè¡š
ããã
ã§è¡šããããååç©ãåæããŠãããä»æ¹ãäžèš
åŒãã
ãåŒäžãNCSã¯ããªã«ã«ããã¹ã¿ãã³ãè¡šãã
NCSã¯ãã®ååŠæ§é äžã®ã¢ããåºã§çµåããŠã
ããã¯ïœâããšãã¬ã³åºãŸãã¯ããªã¡ãã¬ã³åº
ãè¡šãã
ã§è¡šãããå°å
¥ããããã¬ã€ããåºãæããããª
ã«ã«ããã¹ã¿ãã³ãåæããäž¡è
ãåå¿ãããã
ãšã«ãã補é ããããšãã§ããã
å³ã¡ãæè
«çIgGå
ç«ã°ãããªã³ãŸãã¯ãã®ã
ã©ã°ã¡ã³ãã«ãäŸãã°ãåŒããã§è¡šããããæ¶
æ©å€ãåå¿ããããçæç©ããäŸãã°ãïŒâã¡ã«
ã«ãããšã¿ããŒã«ãŸãã¯ãžããªã¹ã¬ã€ããŒã«ã§é
å
ããŠãåå¿(1)ããåŒããã§è¡šãããããªãŒã«
åºãå°å
¥ãããå
ç«ã°ãããªã³ãŸãã¯ãã®ãã©ã°
ã¡ã³ããåŸãã
ïŒäžèšåŒ(1)äžãïœã¯ïŒãïŒã®æŽæ°ãè¡šããïŒä»
æ¹ãããªã«ã«ããã¹ã¿ãã³ããäŸãã°ãåŒãã
ã§è¡šããããæ¶æ©å€ãšåå¿ããããäžèšåŒã
ã
ãåŒäžãNCSåã³ïŒžã®å®çŸ©ã¯åŒããã®å Žå
ãšåãã§ãããïœã¯ïŒãŸãã¯ïŒãè¡šãããã
ã§è¡šãããããã¬ã€ããåºãå°å
¥ãããããªã«ã«
ããã¹ã¿ãã³ãåŸãããããŠãããããŠåŸããã
ããªãŒã«åºãå°å
¥ãããæè
«çIgGå
ç«ã°ãããª
ã³ãŸãã¯ãã®ãã©ã°ã¡ã³ããšããã¬ã€ããåºãå°
å
¥ãããããªã«ã«ããã¹ã¿ãã³ãåå¿ãããããš
ã«ãããæ¬çºæã®éžæç殺现èæ§èçœè€åäœã補
é ããããšãã§ããã
æ¬çºæã®éžæç殺现èæ§èçœè€åäœã®äžã€ã®å
é§ç©è³ªã¯ããªãŒã«åºãæããå
ç«ã°ãããªã³ãŸã
ã¯ãã®ãã©ã°ã¡ã³ãã§ãããããããããªãŒã«åº
ã¯ååŠåŒã§å
·äœçã«èšããåŠããå€éšããå°å
¥ã
ããããªãŒã«åºã®ä»ãå
ç«ã°ãããªã³ãŸãã¯ãã®
ãã©ã°ã¡ã³ãèªäœãããšããšããªãŒã«åºãæããŠ
ããå Žåã«ã¯ãã®ããªãŒã«åºããããã¯ã·ã¹ãã³
ã«åºã¥ããžã¹ã«ãã€ãçµåããã€ãŠããå Žåã«
ã¯ããã®ãžã¹ã«ãã€ãåºããäŸãã°ãéå
ããŠç
æãããããšãã§ããããªãŒã«åºã§ãã€ãŠãã
ãã
æ¬çºæã®éžæç殺现èæ§èçœè€åäœã®è£œé ã«ã
ããŠãå
ç«ã°ãããªã³ãŸãã¯ãã®ãã©ã°ã¡ã³ãã«
æ¶æ©å€ãåå¿ãããå Žåã¯ãå
ç«ã°ãããªã³ãŸã
ã¯ãã®ãã©ã°ã¡ã³ãïŒã¢ã«ã«å¯Ÿããæ¶æ©å€ãïŒã
100ã¢ã«çšããã®ã奜ãŸãããåå¿ã¯å
ç«ã°ãã
ãªã³ãŸãã¯ãã®ãã©ã°ã¡ã³ãã®PHïŒãïŒã®ç·©è¡æ¶²
äžèçœæ¿åºŠã0.5ã100mgïŒmlïŒãã奜ãŸããã¯ïŒ
ã20mgïŒmlïŒã«ãªãããã«èª¿è£œããã溶液ã«ãïŒ
ã40âã§æªæããªããæ¶æ©å€ã®æ°Žæº¶æ¶²ãŸãã¯æ¶æ©
å€ãæ°Žã«æº¶ããªãå Žåã«ã¯ãæ¶æ©å€ãå°éã®ææ©
溶åªãäŸãã°ãïŒïŒ®âãžã¡ãã«ãã«ãã¢ããïŒ
ãžã¡ãã«ã¹ã«ããã·ãïŒïŒïŒïŒâãžã¡ããã·ãšã¿
ã³ïŒã¡ã¿ããŒã«ïŒãšã¿ããŒã«ïŒã¢ã»ãã³çã«æº¶ã
ãã溶液ãæ·»å ããŠè¡ãªããããåå¿æéã¯ãå
å¿ã¹ã±ãŒã«ïŒåå¿æ¡ä»¶ã«ããããäžè¬ã«ïŒæ¥é以
å
ã§ãããåå¿çµäºåŸãéæãŸãã¯ååãµããã®
ã«ã©ã ã¯ãããã°ã©ãã€ãŒã«ãããæªåå¿ã®æ¶æ©
å€åã³äœåååå¿çæç©ãé€ããæ¶æ©å€ã«ãããž
ã¹ã«ãã€ãåºãå°å
¥ãããå Žåã«ã¯ããžã¹ã«ãã€
ãåºã¯ããªãŒã«åºã«éå
ããããããããåå¿ã¯
ããªãŒã«è©Šè¬ïŒäŸãã°ãïŒâã¡ã«ã«ãããšã¿ãŒ
ã«ïŒãžããªã¹ã¬ã€ããŒã«ïŒãéå°ã«çšããäžèšã®
åå¿æž©åºŠïŒåå¿æéãé©çšããŠè¡ããåããäžèš
ã®æ¹æ³ã«ãŠåå¿ç©ã®ç²Ÿè£œãè¡ãããšãã§ããããŸ
ããããªã«ã«ããã¹ã¿ãã³ã«æ¶æ©å€ãçšããŠãã¬
ã€ããåºãå°å
¥ããåå¿æ¡ä»¶ãäžèšã®å
ç«ã°ãã
ãªã³ãŸãã¯ãã®ãã©ã°ã¡ã³ãã«æ¶æ©å€ãåå¿ãã
ãå Žåã®åå¿æ¡ä»¶ãšåæ§ã§ããã
ããªãŒã«åºãçºçãŸãã¯å°å
¥ãããããªãŒã«åº
ãæããå
ç«ã°ãããªã³ãŸãã¯ãã®ãã©ã°ã¡ã³ã
ãšãã¬ã€ããåºãå°å
¥ãããããªã«ã«ããã¹ã¿ã
ã³ãšã®åå¿ã¯ãäž¡è
ãæ··åããŠïŒåå¿æ¶²ã®å¥œãŸã
ãPHã¯ïŒãïŒã§ã奜ãŸããèçœæ¿åºŠã¯ïŒã20mgïŒ
mlã§ããïŒãïŒã40âã§ïŒã24æéè¡ããããäž
èšæ¹æ³ã«ãã€ãŠåŸãããå
ç«ã°ãããªã³åã¯ãã®
ãã©ã°ã¡ã³ããšããªã«ã«ããã¹ã¿ãã³ã®è€åäœ
ã®ãåå¿æ··åç©ããã®åé¢ã粟補ã¯éåžžçšããã
ãæäœãäŸãã°ãååãµããã®ã«ã©ã ã¯ãããã°
ã©ãã€ãŒã«ãã€ãŠè¡ãªãããšãã§ããã
æ¬çºæã®éžæç殺现èæ§èçœè€åäœã¯ãç现è
çã®æšç现èã«å¯Ÿãæ¯æ§ãçºæ®ããããªã«ã«ãã
ã¹ã¿ãã³ããæãæ§æéšåãšãæšç现èãéžæç
ã«èªèããããªã«ã«ããã¹ã¿ãã³ãæšç现èã«éž
æçã«å°éãããããã€ãªã¢ãŒã§ããå
ç«ã°ãã
ãªã³ãŸãã¯ãã®ãã©ã°ã¡ã³ãããæãæ§æéšåã
æãããããäž¡æ§æéšåãååŠçã«å®å
šãªçµåã«
ãã€ãŠçµåãããŠããã®ã§ãæšç现èã«å¯Ÿãã现
èæ¯æ§ãéžæçã«ãããå¹çããçºæ®ã§ãããšã
ãç¹åŸŽãæããŠããããŸããããè€åäœã¯ãæ¬çº
æã®æ¹æ³ã«ãã€ãŠçŽåºŠé«ã補é ããããšãã§ã
ãã
以äžãå®æœäŸã«ããæ¬çºæã詳述ããã
å®æœäŸ ïŒ
(ã€) æããŠã¹ä¹³çMM46ã¢ãã¯ããŒã³æäœã®èª¿è£œ
现èèåæ³ã«ããåŸãããæMM46IgG2bæäœ
ç£çæ§ãã€ããªããŒãïŒç¬æžå 倧ãããžã€ãŒãã«
ãªã ã€ã ãããžãŒïŒJ.ImmunolïŒïŒç¬¬128å·»ã
201ã205é ã1982幎åç
§ïŒããããŒãããŠã¹15å¹
ã®è
¹è
ã«ãäžå¹åœãïŒÃ107åæ¥çš®ãã10æ¥åŸã«
è
¹æ°Žæ¶²ãæ¡åããåŸãããè
¹æ°Žæ¶²50mlãïŒã®
0.1Mãªã³é
žç·©è¡æ¶²ïŒPH8.0ïŒã«ååéæãããé
æå
液ãåãç·©è¡æ¶²ã§ååã«å¹³è¡¡åãããããã
ã€ã³ïŒ¡ã»ã»ãã¢ããŒã¹ã«ã©ã ïŒã«ã©ã ãµã€ãº1.5
Ã12.5cmïŒã«ãããŠãååã«çŽ éãèçœãæµãåº
ããåŸã0.1Mã¯ãšã³é
žç·©è¡æ¶²ïŒPH5.0ïŒã§äžçŽè
çœã溶åºãããã®åŸ0.1Mã¯ãšã³é
žç·©è¡æ¶²ïŒPH
3.0ïŒã§åžçããŠããIgG2bã溶åºãã溶åºæ¶²ã®
PHã2MTrisâHCç·©è¡æ¶²ïŒPH8.2ïŒã§äžæ§ã«ã
ã©ãããã®åŸïŒã®20mMãªã³é
žç·©è¡æ¶²ïŒPH7.5ïŒ
ã«ååéæãã105mgïŒ17.7mlïŒã®æMM46ã¢ã
ã¯ããŒã³æäœïŒIgG2bïŒãåŸãããŸããæ£åžžããŠ
ã¹è¡æž
50mlãããäžèšãšåæ§ã«ããŠMM46ã«å¯Ÿã
ã芪ååããããªãIgG2bïŒä»¥äžããéå
ç«
IgG2bããšããïŒ25mgïŒ7.0mlïŒãåŸãã
(ã) ããªãŒã«åºããã€IgG2bæäœã®èª¿è£œäžèš(ã€)ã§
åŸãããæMM46ã¢ãã¯ããŒã³æäœIgG2b27.3
mgïŒ4.6mlã0.182ÎŒmoleïŒã«ïŒ®âãµã¯ã·ã³ã€ã
ãžã«ïŒâïŒïŒâããªãžã«ãžããªïŒããããªããŒ
ãïŒä»¥äžSPDPãšç¥ãïŒã®20mMãšã¿ããŒã«æº¶
液36.4ÎŒlïŒIgG2bã®ïŒååœéïŒãå ãã宀枩ã§30
åéåå¿ãããåŸãåå¿æ¶²ã«ã2MTrisâHC
ç·©è¡æ¶²ïŒPH7.5ïŒãïŒïŒ10容éã2M2âMEã
10ÎŒlïŒSPDPã«å¯ŸããŠ30ååœéïŒå ããŠ37âã§
ïŒæéã€ã³ããŠããŒãããã
次ãã§åå¿æ¶²ã20mMãªã³é
žç·©è¡æ¶²ïŒPH7.5ïŒ
ã§å¹³è¡¡åãããŠããã»ãã¢ããã¯ã¹ïŒ§â25ã«ã©
ã ã«ãããäœååç©è³ªãåãé€ããçŽ20mg
ïŒ4.76mlïŒã®ããªãŒã«åºãå°å
¥ãããæ
MM46IgG2bæäœãåŸããéå
ç«Ig2bã«ã€ããŠ
ãåæ§ã«ããŠã25mgã®IgG2bããçŽ20mgïŒ7.9
mlïŒã®ããªãŒã«åºãå°å
¥ãããIgG2bãåŸãã
(ã) ïœâãã¬ã€ãããã³ãŸã€ã«ããªã«ã«ããã¹ã¿
ãã³ã®èª¿è£œ
é®å
äžã«ããªã«ã«ããã¹ã¿ãã³ïŒä»¥äžNCSãš
ç¥ãïŒ14.3mgïŒ5.2mlïŒãå«ã50mMãªã³é
žç·©è¡æ¶²
ïŒPH7.0ïŒã«ãâãµã¯ã·ã³ã€ããžã« ïœâãã¬ã€
ãããã³ãŸãšãŒãïŒä»¥äžSMBãšç¥ãïŒã®ïŒ®ïŒ
Nâ²âãžã¡ãã«ãã«ã ã¢ãã溶液ïŒ173mMïŒ0.15
mlãå ãã23âã§30åéåå¿ããããåå¿æ¶²ãé
å¿ãäžæž
ã50mMãªã³é
žç·©è¡æ¶²ïŒPH6.2ïŒã§å¹³è¡¡
åãããŠããã»ãã¢ããã¯ã¹ïŒ§â25ã«ã©ã ïŒïŒcm
Ã36cmïŒã«ãããæªåå¿ã®SMBçã®äœååç©è³ª
ãé€ããïœâãã¬ã€ãããã³ãŸã€ã«ããªã«ã«ãã
ã¹ã¿ãã³ïŒä»¥äžNCSâMBãšç¥ãïŒ9.9mgïŒ4.5mlïŒ
ãåŸãã
ãªããçæç©ã®äžéš100ÎŒlã«10ååœéã®ãžãã
ãããšãã«âã·ã¹ãã€ã³ïŒä»¥äžDNPâã·ã¹ãã€
ã³ãšç¥ãïŒãå ã23âã§ïŒæéã€ã³ããŠããŒã·ãš
ã³ããççé£å¡©æ°Žã§å¹³è¡¡åããŠããã»ãã¢ããã¯
ã¹ïŒ§â25ã«éããæªåå¿ã®DNPâã·ã¹ãã€ã³ã
é€ããåŸãããè©Šæã®278nmãš361nmã®åžå
床ã
枬å®ãããšããïŒNCSE1%1cmïŒ278nmïŒ15ïŒDNP
âã·ã¹ãã€ã³E%1cmïŒ361nmïŒ17000ïŒãå¹³åããŠ
NCS1åããã0.32åã®ïœâãã¬ã€ãããã³ãŸã€
ã«åºãå°å
¥ãããŠããããšãããã€ãã
(ã) æMM46IgG2bæäœãšNCSã®è€åäœã®äœè£œ
äžèš(ã)ã®åŠãããŠåŸãããããªãŒã«åºãå°å
¥ã
ããæMM46IgG2bæäœ20mgïŒ4.76mlïŒã«äžèš(ã)
ã®åŠãããŠåŸãããNCSâMBã4.73mgïŒ2.15mlïŒ
å ããæ°Žé
žåãããªãŠã ã§PH7.0ã«åãããŠïŒâ
ã§äžæ©åå¿ããããåå¿çµäºåŸåå¿æ¶²ãççé£å¡©
æ°Žã§å¹³è¡¡åãããŠããã»ãã¢ããã¯ã¹ïŒ§â150ã¹
ãŒããŒãã¢ã€ã³ã«ã©ã ïŒ1.5Ã89cmïŒã«ããã第
ïŒå³ã®æç·éšåã®ç»åãéãæ¿çž®ããæ¬çºæã®è€
åäœãå«ãçæç©20.8mlïŒ6.1mlïŒãåŸããåŸã
ããçæç©ãã©ãŠãªã«ç¡«é
žãããªãŠã ã»ããªã¢ã¯
ãªã«ã¢ããã²ã«é»æ°æ³³åïŒä»¥äžSDSâPAGEãšç¥
ãïŒã«ãã解æãããšããã第ïŒå³ã®ãã€ã¹ã¯ïŒ
ã«ç€ºããåŠããã³ãã®ãã¿ãŒã³ãåŸããããã®ç
æç©ã¯æªåå¿ã®æMM46IgG2bæäœïŒååéçŽ
15.5äžïŒãšãIgG2bæäœã«NCSãïŒåçµåããã
ã®ïŒååéçŽ17äžïŒãšIgG2bæäœã«NCSãïŒåçµ
åãããã®ïŒååéçŽ18äžïŒãšãããªãããšãã
ãã€ãã
éå
ç«IgG2bæäœãçšããåèšãšåæ§ã«ããŠ
NCSãšã®åå¿ãè¡ãªã€ããšããããã®çæç©ã®
SDSâPAGEã«ãã解æçµæã¯ç¬¬ïŒå³ã®ãã€ã¹ã¯
ïŒã®åŠãã§ãããæMM46IgG2bæäœã®å Žåãšé¡
䌌ããŠããã
ãªãã第ïŒå³ã®ãã€ã¹ã¯ïŒã¯æMM46IgG2bæ
äœã®ãã³ãã®ãã¿ãŒã³ã§ããã
(ã) ããŠã¹ã«ãããæ²»çå®éš
äžèš(ã)ã®åŠãããŠäœè£œããæMM46IgG2bæäœ
ãšNCSã®è€åäœãå«ãçæç©ïŒä»¥äžåã«æ
MM46IgG2bæäœãšNCSã®è€åäœãšããïŒã®ã
MM46è
«çã移æ€ããããŠã¹ã«å¯Ÿããæ²»çå¹æã
æ€èšããã
å³ã¡ãäžçŸ€ïŒå¹ã®C3HããŠã¹ã«ïŒÃ105åã®
MM46现èãè
¹è
å
ã«ç§»æ€ãã移æ€24æéåŸã«é
è泚å°ã«ããæ€äœïŒæMM46IgG2bæäœãšNCSã®
è€åäœãéå
ç«IgG2bæäœãšNCSã®è€åäœãæ
MM46IgG2bæäœãšNCSã®ïŒïŒïŒæ··åç©ã®50ÎŒg
ãŸãã¯500ÎŒgïŒãæäžããå矀ã®ããŠã¹ã®å¯¿åœã
æ¯èŒããæMM46IgG2bæäœãšNCSã®è€åäœã®æ
è
«ç掻æ§ãæ€èšããã
ãã®çµæã第ïŒå³ã«ç€ºãããéå
ç«IgG2bæäœ
ãšNCSã®è€åäœã¯500ÎŒgæäžããŠãæè
«çæ§ã瀺
ãããããŠã¹ã®å¯¿åœã¯é£å¡©æ°Žæäžã®å¯Ÿç
§çŸ€ãšã»ãŒ
åãã§ãããå
šããŠã¹ãè
«ç移æ€åŸ15æ¥ãŸã§ã«æ»
亡ããïŒç¬¬ïŒå³(b)ïŒãæMM46IgG2bæäœãšNCS
ã®ïŒå¯ŸïŒæ··åç©ã§ã¯ã500åã³50ÎŒgæäžããå Ž
åãè¥å¹²ã®æè
«çå¹æãã¿ãããããäžå¹ã®ããŠ
ã¹ãé·æéçåããã«æ¢ãŸã€ãïŒç¬¬ïŒå³(c)ïŒãã
ãã«å¯ŸããæMM46IgG2bæäœãšNCSã®è€åäœæ
äžçŸ€ã§ã¯ã500ÎŒgæäžããå ŽåïŒå¹ã®ããŠã¹ãé·
æéçåããæ¬çºæã®è€åäœã«åŒ·ãæè
«çæ§ãã
ãããšãããã€ãïŒç¬¬ïŒå³(a)ïŒã
å®æœäŸ ïŒ
(ã€) æããŠã¹çœè¡ç
L1210IgGã®èª¿è£œããŠã¹çœè¡
ç
L1210现èïŒÃ106åãããã€ã³ãå®å
šã¢ãž
ãŠãã³ããšã®ãšãã«ãžãšã³ãšãã家å
ã«éè泚
å°ããããã®åŸæŽã«ãïŒé±éééã§ïŒåããã
ããçŽïŒÃ106åã®L1210现èãã¢ãžãŠãã³ã
ãšå
±ã«ç®äžæ³šå°ããæçµæäžæ¥ããïŒæ¥åŸã«æ¡
è¡ãããåŸãããè¡æ¶²ãããŒã«ããè¡æž
ãåé¢
ãããã®è¡æž
ã56âã30åéå ç±ãéååã
ããããããŠåŸãããæL1210è¡æž
200mlã«ã
ç¡«å®ã®é£œå氎溶液200mlãå ããŠãçããæ²æŸ±
ãé å¿åé¢ã«ãã€ãŠååããããã®æ²æŸ±ã
0.01Mãªã³é
žç·©è¡æ¶²ïŒPH7.6ïŒ50mlã«æº¶è§£ãã
æŽã«åç·©è¡æ¶²ã«å¯ŸããŠååã«éæããããã®é
æå
液ãåãç·©è¡æ¶²ã§å¹³è¡¡åããDEAEã»ã«ã
ãŒã¹ã«ã©ã ã¯ãããã°ã©ãã€ãŒïŒã«ã©ã ãµã€ãº
ïŒcmÃ94cmïŒã«ãããŠãæªåžçåç»ãšããŠæ
L1210IgGãå«ã溶液ãåŸãã
(ã) å
ç«ã°ãããªã³ããïŒabïŒâ²2ãã©ã°ã¡ã³ã
ã®åé¢
äžèš(ã€)ã®åŠãããŠåŸãããæL1210IgGã®1.2ïœ
ã0.1Mé
¢é
žç·©è¡æ¶²ïŒPH4.5ïŒ40mlã«æº¶è§£ãã24mg
ã®ããã·ã³ãæ·»å ããŠã37âã§çŽ18æéå解ãã
åŸãå解çæç©ãççé£å¡©æ°Žäžã§ã»ãã¢ããã¯ã¹
G200ã«ã©ã ã¯ãããã°ã©ãã€ãŒïŒã«ã©ã ãµã€ãº
3.5cmÃ140cmïŒã«ãããŠãååéçŽ10äžã®ãšãã
ã«æµåºããèçœãšããŠçŽç²ãªïŒŠïŒabïŒâ²2ãã©ã°ã¡
ã³ããåŸãã
(ã) Fabâ²ãã©ã°ã¡ã³ãã®èª¿è£œ
äžèš(ã)ã®åŠãããŠåŸãããïŒabïŒâ²2ãã©ã°ã¡
ã³ã18.4mgãå«ã0.01Mããªã¹ã»å¡©é
žâ0.14Må¡©
åãããªãŠã â2mMEDTA溶液ïŒPH8.3ïŒ2.0ml
ã«ã150mMã®ïŒâã¡ã«ã«ãããšã¿ããŒã«æ°Žæº¶æ¶²
ã0.02mlå ããŠã37âã§ïŒæééå
ãããåå¿
åŸããã®æº¶æ¶²ã5mMé
¢é
žç·©è¡æ¶²â0.14Må¡©åã
ããªãŠã â1mMEDTA溶液ïŒPH5.5ïŒïŒä»¥äžã
ANEç·©è¡æ¶²ãšç¥ãïŒã§å¹³è¡¡åããã»ãã¢ããã¯
ã¹G25ã«ã©ã ã¯ãããã°ã©ãã€ãŒïŒ1.0cmÃ20cmïŒ
ã«ãããŠïŒâã¡ã«ã«ãããšã¿ããŒã«ãé€å»ããã
ãªãŒã«åºïŒåãæããFabâ²ãã©ã°ã¡ã³ããåŸãã
(ã) æããŠã¹çœè¡ç
L1210IgGãã©ã°ã¡ã³ã
Fabâ²ãšNCSã®è€åäœã®äœè£œ
äžèš(ã)ã®åŠãããŠåŸãããæL1210IgGã®
Fabâ²ãã©ã°ã¡ã³ãïŒmgïŒïŒmlïŒã«ãå®æœäŸïŒã®
(ã)ã®åŠãããŠåŸãããNCSâMBã3.5mgïŒ1.6mlïŒ
å ãã0.5Mãªã³é
žç·©è¡æ¶²ïŒPH7.0ïŒãïŒïŒ10容é
å ããïŒâã§äžæ©åå¿ããããåå¿çµäºåŸãçç
é£å¡©æ°Žã§å¹³è¡¡åãããŠããã»ãã¢ããã¯ã¹ïŒ§â
150ã¹ãŒããŒãã¢ã€ã³ã«ã©ã ïŒ1.5cmÃ89cmïŒã«ã
ã€ãŠè€åäœã粟補ããæL1210IgGã®Fabâ²ãã©ã°
ã¡ã³ããšNCSã®è€åäœïŒmgïŒïŒmlïŒãåŸããåŸ
ãããè€åäœã«ã¯ãSDSâPAGEã«ãã解æãã
ãšãããååéçŽïŒäžã®Fabâ²ãšååéçŽïŒäžã®
èçœïŒè€åäœïŒãå«ãŸããŠããããšãå€ã€ãã
ãªããæ1210IgGã®ãã©ã°ã¡ã³ãã¯ããªãŒã«åº
ïŒåãå«ãFabâ²ã§ãããåŸã€ãŠïŒåã®NCSãçµ
åããŠãããåŸãããèçœè€åäœã¯æ¬çºæã®äžè¬
åŒããã«ãããŠïœïŒïŒã®ååç©ã§ããã[Formula] p-nitrophenoxy group, 2,4-dinitrophenoxy group, 2,4,
Examples include 5-lolichlorophenoxy group and bentachlorophenoxy group. Specific examples of the alcohol residue of the imidoester represented by Q include methoxy and ethoxy groups. Specific examples of the halogen atom represented by R include chlorine, bromine, and iodine. X in the above formula [] is the following formula [] [In the formula, X 4 represents a m-phenylene group or a trimethylene group. The definition of Z is the same as the formula []. ] Derived from X 4 of the crosslinking agent represented by Specific examples of the alcohol residue of the active ester represented by Z are the same as in the case of the above formula []. Specific examples of the crosslinking agent include N-succinimidyl 3-(2-pyridyldithio)propionate as a crosslinking agent represented by the formula [], and N-hydroxysuccinimide benzoate as a crosslinking agent represented by the formula []. Imidoester and maleimidoacetic acid 2,4-dinitrophenol ester can be mentioned. The selective cell-killing protein complex of the present invention has anti-tumor properties.
By generating or introducing a thiol group into IgG immunoglobulin or its fragment, the following formula [] [wherein Ab represents an antitumor IgG immunoglobulin or a fragment thereof, and Ab is bonded through an amino group in its chemical structure. m represents 0 or 1. S represents a sulfur atom, but when m is 0, S
m is derived from a thiol group originally contained in the chemical structure of the antitumor IgG immunoglobulin or its fragment, and when m is 1, it is derived from a thiol group contained in the introduced organic group. n1 represents an integer from 1 to 5. ] A compound represented by is synthesized, and on the other hand, the following formula [] [In the formula, NCS represents neocarzinostatin,
NCS is bonded through amino groups in its chemical structure. X represents m-phenylene group or trimethylene group] It can be produced by synthesizing neocarzinostatin having an introduced maleimide group represented by the following and reacting the two. That is, anti-tumor IgG immunoglobulin or a fragment thereof is reacted with, for example, a crosslinking agent represented by the formula [], and the product is reduced with, for example, 2-mercaptoethanol or dithiothreitol [reaction (1)]. , an immunoglobulin or a fragment thereof into which a thiol group represented by formula [X] has been introduced is obtained. (In the above formula (1), p represents an integer of 1 to 5.) On the other hand, neocarzinostatin is expressed by the formula []
It is reacted with a crosslinking agent represented by the following formula [X
] [In the formula, the definitions of NCS and X are the same as in the case of the formula []. q represents 1 or 2. ] Obtain neocarcinostatin into which a maleimide group represented by the following is introduced. Then, the selective cell-killing protein complex of the present invention is produced by reacting the thus obtained antitumor IgG immunoglobulin or its fragment into which a thiol group has been introduced with neocarzinostatin into which a maleimide group has been introduced. can be manufactured. One precursor of the selective cell-killing protein complex of the present invention is an immunoglobulin or a fragment thereof having a thiol group; In addition, if the immunoglobulin or its fragment itself originally has a thiol group, or if it has a cystine-based disulfide bond, the disulfide group can be reduced, for example. It may also be a thiol group that can be In the production of the selective cell-killing protein complex of the present invention, when reacting an immunoglobulin or its fragment with a crosslinking agent, 1 to 1 to 10% of the crosslinking agent is added to 1 mole of the immunoglobulin or its fragment.
Preferably, 100 mol is used. The reaction is carried out using an immunoglobulin or its fragment at a protein concentration of 0.5 to 100 mg/ml (more preferably 1
~20mg/ml) in a solution prepared with 0
An aqueous solution of the crosslinking agent or, if the crosslinking agent is not soluble in water, a small amount of an organic solvent such as N,N-dimethylholdamide,
It is carried out by adding a solution dissolved in dimethyl sulfoxide, 1,2-dimethoxyethane, methanol, ethanol, acetone, etc. The reaction time depends on the reaction scale and reaction conditions, but is generally within 2 days. After the reaction is completed, unreacted crosslinking agents and low-molecular reaction products are removed by dialysis or molecular sieve column chromatography. When a disulfide group is introduced by a crosslinking agent, the disulfide group is reduced to a thiol group, but this reaction uses an excess of a thiol reagent (e.g., 2-mercaptoethal, dithiothreitol) and the above reaction temperature. , reaction time can be applied, and the reactant can be purified by the same method as described above. Furthermore, the reaction conditions for introducing a maleimide group into neocarzinostatin using a crosslinking agent are the same as those for reacting the crosslinking agent with the above-mentioned immunoglobulin or its fragment. The reaction between an immunoglobulin having a thiol group or a fragment thereof having a thiol group generated or introduced therein and neocarzinostatin having a maleimide group introduced can be carried out by mixing the two (the preferred pH of the reaction solution is 5 to 8, The preferred protein concentration is 1-20mg/
ml) at 0-40°C for 2-24 hours. The complex of immunoglobulin or its fragment and neocarzinostatin obtained by the above method can be separated and purified from the reaction mixture by a commonly used procedure, such as molecular sieve column chromatography. can. The selective cell-killing protein complex of the present invention has a component consisting of neocarzinostatin that is toxic to target cells such as cancer cells, and a component that selectively recognizes target cells and targets neocarzinostatin. It has a component consisting of immunoglobulin or its fragment, which is a carrier that selectively reaches cells, and both components are linked by a chemically safe bond, so it is selective for cytotoxicity against target cells. It has the characteristic of being able to perform effectively and efficiently. Moreover, such a complex can be produced with high purity by the method of the present invention. Hereinafter, the present invention will be explained in detail with reference to Examples. Example 1 (a) Preparation of anti-mouse breast cancer MM46 monoclonal antibody Anti-MM46 IgG2b antibody-producing hybridoma obtained by cell fusion method (Seto Kadai et al., Journal of Immunology (J. Immunol), Vol. 128,
201-205, 1982) was inoculated into the peritoneal cavity of 15 nude mice at 2 x 10 7 per mouse, and after 10 days, the ascites fluid was collected.
It was thoroughly dialyzed against 0.1M phosphate buffer (PH8.0). The dialysis solution was thoroughly equilibrated with the same buffer using a Protein A/Sepharose column (column size 1.5).
x 12.5cm) to thoroughly wash out the protein that passed through, elute the impure protein with 0.1M citrate buffer (PH5.0), and then elute the impure protein with 0.1M citrate buffer (PH5.0).
3.0) to elute the adsorbed IgG2b and collect the eluate.
Return the pH to neutral with 2MTris-HC buffer (PH8.2), then add 20mM phosphate buffer (PH7.5) in step 5.
After thorough dialysis, 105 mg (17.7 ml) of anti-MM46 monoclonal antibody (IgG2b) was obtained. In addition, from 50 ml of normal mouse serum, we collected IgG2b (hereinafter referred to as "non-immune") that does not have affinity for MM46 in the same manner as above.
25 mg (7.0 ml) of IgG2b was obtained. (b) Preparation of IgG2b antibody with thiol group Anti-MM46 monoclonal antibody IgG2b27.3 obtained in (a) above
36.4 ÎŒl of a 20 mM ethanol solution (4 times equivalent of IgG2b) of N-succinimidyl 3-(2-pyridyldithio)propionate (hereinafter abbreviated as SPDP) was added to mg (4.6 ml, 0.182 ÎŒmole), and
After reacting for minutes, add 2MTris-HC to the reaction solution.
1/10 volume of buffer solution (PH7.5), 2M2-ME
10 Όl (30 times equivalent to SPDP) was added and incubated at 37° C. for 1 hour. Then, the reaction solution was diluted with 20mM phosphate buffer (PH7.5).
Approximately 20 mg of
(4.76ml) of anti-thiol group introduced
MM46IgG2b antibody was obtained. Similarly, for non-immune Ig2b, approximately 20 mg (7.9
ml) of IgG2b into which a thiol group was introduced was obtained. (c) Preparation of m-maleimidobenzoyl neocarzinostatin N-succinimidyl m - N of maleimidobenzoate (hereinafter abbreviated as SMB),
Nâ²-dimethylformamide solution (173mM) 0.15
ml was added and reacted at 23°C for 30 minutes. The reaction solution was centrifuged and the supernatant was transferred to a Sephadex G-25 column (1 cm) equilibrated with 50 mM phosphate buffer (PH6.2).
x 36 cm), remove unreacted low-molecular substances such as SMB, and prepare 9.9 mg (4.5 ml) of m-maleimidobenzoyl neocarcinostatin (hereinafter abbreviated as NCS-MB).
I got it. In addition, 10 times the equivalent of dinitrophenyl-cysteine (hereinafter abbreviated as DNP-cysteine) was added to 100 Όl of a portion of the product, incubated at 23°C for 1 hour, and transferred to Cephadex G-25 equilibrated with physiological saline. After removing unreacted DNP-cysteine, the absorbance of the resulting sample at 278 nm and 361 nm was measured (NCSE 1 % 1 cm, 278 nm = 15, DNP
- Cysteine E% 1 cm, 361 nm = 17000), on average
It was found that 0.32 m-maleimidobenzoyl groups were introduced per NCS. (d) Preparation of a complex of anti-MM46IgG2b antibody and NCS 20mg (4.76ml) of the anti-MM46IgG2b antibody into which a thiol group was introduced as obtained in (b) above was added to the above (c).
4.73 mg (2.15 ml) of NCS-MB obtained as follows.
Add sodium hydroxide to adjust the pH to 7.0 at 4â.
The mixture was allowed to react overnight. After the reaction was completed, the reaction solution was applied to a Cephadex G-150 Superfine column (1.5 x 89 cm) equilibrated with physiological saline, and the fractions shown in the shaded area in Figure 2 were collected and concentrated to obtain the complex of the present invention. 20.8 ml (6.1 ml) of containing product were obtained. When the obtained product was analyzed by sodium lauryl sulfate polyacrylamide gel electrophoresis (hereinafter abbreviated as SDS-PAGE), disk 2 in Figure 3 was found.
A band pattern as shown in Figure 1 was obtained, and this product was composed of unreacted anti-MM46 IgG2b antibody (molecular weight approx.
155,000), an IgG2b antibody bound to one NCS (molecular weight approximately 170,000), and an IgG2b antibody bound to two NCS (molecular weight approximately 180,000). Same as above using non-immune IgG2b antibody.
When the reaction with NCS was carried out, the product was
The analysis results by SDS-PAGE were as shown in disk 3 of FIG. 3, and were similar to those for the anti-MM46 IgG2b antibody. Note that disk 1 in FIG. 1 is the band pattern of anti-MM46 IgG2b antibody. (e) Therapeutic experiment in mice The product containing the complex of anti-MM46IgG2b antibody and NCS prepared as described in (d) above (hereinafter simply referred to as anti-MM46 IgG2b antibody and NCS)
MM46IgG2b antibody and NCS complex)
We investigated the therapeutic effects on mice transplanted with MM46 tumors. That is, 3 Ã 10 5 mice were administered to each group of 5 C3H mice.
MM46 cells were transplanted intraperitoneally, and 24 hours after transplantation, samples (complex of anti-MM46 IgG2b antibody and NCS, complex of non-immune IgG2b antibody and NCS, anti-MM46 IgG2b antibody and NCS,
50ÎŒg of 1:1 mixture of MM46IgG2b antibody and NCS
The lifespan of mice in each group was compared, and the antitumor activity of the complex of anti-MM46 IgG2b antibody and NCS was examined. The results are shown in Figure 4. The conjugate of non-immune IgG2b antibody and NCS showed no antitumor activity even when administered at 500 ÎŒg, and the lifespan of the mice was similar to that of the saline-treated control group, with all mice dying by 15 days after tumor implantation. (Figure 4(b)). Anti-MM46IgG2b antibody and NCS
A 1:1 mixture of 500 and 50 ÎŒg showed some antitumor effects, but only one mouse survived for a long period of time (Figure 4(c)). On the other hand, in the group administered with the anti-MM46IgG2b antibody and NCS complex, three mice survived for a long period of time when 500 ÎŒg was administered, indicating that the complex of the present invention has strong antitumor properties (Figure 4). (a)). Example 2 (a) Preparation of anti-mouse leukemia L1210 IgG 1Ã10 6 mouse leukemia L1210 cells were made into an emulsion with Freund's complete adjuvant and intravenously injected into rabbits. Thereafter, approximately 1Ã10 6 L1210 cells were subcutaneously injected together with adjuband three times at one-week intervals, and blood was collected 8 days after the final administration. The obtained blood was pooled, the serum was separated, and the serum was inactivated by heating at 56°C for 30 minutes. To 200 ml of the anti-L1210 serum obtained in this way,
200 ml of a saturated aqueous solution of ammonium sulfate was added, and the resulting precipitate was separated by centrifugation. This precipitate
Dissolve in 50ml of 0.01M phosphate buffer (PH7.6),
Furthermore, it was thoroughly dialyzed against the same buffer. This dialyzed solution was subjected to DEAE cellulose column chromatography (column size 3 cm x 94 cm) equilibrated with the same buffer, and the unadsorbed fraction was treated with anti-antibiotics.
A solution containing L1210IgG was obtained. (b) Separation of F(ab)â² 2 fragment from immunoglobulin 1.2 g of anti-L1210 IgG obtained as in (b) above
Dissolve in 40ml of 0.1M acetate buffer (PH4.5) and add 24mg
After adding pepsin and decomposing at 37°C for about 18 hours, the decomposition products were separated into physiological saline.
G200 column chromatography (column size
3.5 cm x 140 cm), a pure F(ab)' 2 fragment was obtained as a protein flowing out at a molecular weight of approximately 100,000. (c) Preparation of Fab' fragment 2.0ml of 0.01M Tris-HCl-0.14M sodium chloride-2mMEDTA solution (PH8.3) containing 18.4mg of F(ab)' 2 fragment obtained as in (b) above.
0.02ml of 150mM 2-mercaptoethanol aqueous solution was added to the mixture, and the mixture was reduced at 37°C for 1 hour. After the reaction, the solution was mixed with 5mM acetate buffer - 0.14M sodium chloride - 1mM MEDTA solution (PH5.5) (hereinafter referred to as
Sephadex G25 column chromatography (1.0cm x 20cm) equilibrated with ANE buffer)
2-mercaptoethanol was removed to obtain a Fab' fragment having one thiol group. (d) Anti-mouse leukemia L1210 IgG fragment
Preparation of complex of Fabâ² and NCS The anti-L1210 IgG obtained as in (c) above
5 mg (2 ml) of the Fab' fragment was added to the Fab' fragment of Example 1.
3.5 mg (1.6 ml) of NCS-MB obtained as in (c)
In addition, 1/10 volume of 0.5M phosphate buffer (PH7.0) was added, and the mixture was reacted overnight at 4°C. After the reaction is complete, Cephadex G- is equilibrated with physiological saline.
The complex was purified using a 150 Superfine column (1.5 cm x 89 cm) to obtain 6 mg (4 ml) of a complex of anti-L1210 IgG Fab' fragment and NCS. When the obtained complex was analyzed by SDS-PAGE, it was found that it contained Fab' with a molecular weight of about 50,000 and protein (complex) with a molecular weight of about 60,000. The anti-1210 IgG fragment is Fab' containing one thiol group, and therefore has one NCS bound to it, and the resulting protein complex is a compound of the present invention where n=1 in the general formula []. It is.
第ïŒå³ã®ã€ã¯ãå
ç«ã°ãããªã³ã®åºæ¬æ§é ã瀺
ãæš¡åŒå³ããã¯ããå
ç«ã°ãããªã³ã®IgG1ã®æ§
é ã瀺ãæš¡åŒå³ã§ããã第ïŒå³ã¯ãå®æœäŸïŒ(ã)ã§
åŸãåå¿çæç©ã®ãã»ãã¢ããã¯ã¹ïŒ§â150ã¹ãŒ
ããŒãã¢ã€ã³ã»ã«ã©ã ã¯ãããã°ã©ãã€ãŒã«ãã
ãèçœæµåºãã¿ãŒã³ã§ããã第ïŒå³ã¯ãSDSâ
PAGEã®ãã¿ãŒã³ã§ããããã€ã¹ã¯ïŒã¯æ
MM46IgG2bæäœããã€ã¹ã¯ïŒã¯å®æœäŸïŒã§åŸã
ããæMM46IgG2bæäœãšNCSã®è€åäœããã€ã¹
ã¯ïŒã¯åããå®æœäŸïŒã§åŸãããéå
ç«IgG2bãš
NCSã®è€åäœãSDSâPAGEã«ãããŠåŸããã
ãã³ãã®ãã¿ãŒã³ã§ããã第ïŒå³ã¯ãå®æœäŸïŒ(ã)
ã§è¡ãªã€ãæMM46æäœãšNCSã®è€åäœã®æè
«
çæ§ããMM46è
«çã移æ€ããããŠã¹ã«å¯Ÿããæ²»
çå¹æã§èª¿ã¹ãçµæã§ãããããŠã¹ã®çåçãã
è
«ç移æ€åŸã®æ¥æ°ã«å¯ŸããŠç€ºããå³ã§ãããïœã¯
æMM46IgG2bãšNCSãšã®è€åäœã®å Žåã§ãââ
âã¯ççé£å¡©æ°Žããâââã¯500ÎŒgãââ³âã¯50ÎŒg
ã®è€åäœãæäžããå Žåã®çåçã瀺ããïœã¯é
å
ç«IgG2bãšNCSãšã®è€åäœã®å Žåã§ãâââã¯
ççé£å¡©æ°Žããâââã¯500ÎŒgãââ³âã¯50ÎŒgã®è€
åäœãæäžããå Žåã®çåçã瀺ããïœã¯æ
MM46IgG2bãšNCSãïŒïŒïŒã®å²åã®æ··åç©ã®å Ž
åã§ãâââã¯ççé£å¡©æ°Žããâââã¯500ÎŒgãâ
â³âã¯50ÎŒgã®æ··åç©ãæäžããå Žåã®çåçã
瀺ãã
In FIG. 1, A is a schematic diagram showing the basic structure of immunoglobulin, and B is a schematic diagram showing the structure of IgG1, a human immunoglobulin. FIG. 2 shows the protein efflux pattern of the reaction product obtained in Example 1 (d) in Sephadex G-150 Superfine column chromatography. Figure 3 shows the SDS-
PAGE pattern, disk 1 is anti-
MM46IgG2b antibody, disk 2 is a complex of anti-MM46IgG2b antibody obtained in Example 1 and NCS, and disk 3 is a complex of non-immune IgG2b obtained in Example 1 as well.
This is a band pattern obtained by subjecting the NCS complex to SDS-PAGE. Figure 4 shows Example 1 (E)
These are the results of investigating the antitumor properties of the complex of anti-MM46 antibody and NCS in terms of the therapeutic effect on mice transplanted with MM46 tumors.
FIG. 3 is a graph plotted against the number of days after tumor implantation. a is the case of the complex of anti-MM46 IgG2b and NCS, -â
-: Physiological saline, -â-: 500ÎŒg, -â³-: 50ÎŒg
The figure shows the survival rate when the complex was administered. b shows the survival rate in the case of a complex of non-immune IgG2b and NCS, -â- shows the survival rate when physiological saline was administered, -â- shows 500 ÎŒg of the complex, and -Î- shows the survival rate when 50 ÎŒg of the complex was administered. c is anti
In the case of a mixture of MM46IgG2b and NCS at a ratio of 1:1, -â- is physiological saline, -â- is 500 ÎŒg, -
Î- indicates the survival rate when 50 ÎŒg of the mixture was administered.
Claims (1)
ãããªã³ãŸãã¯ãã®ãã©ã°ã¡ã³ããšããªã«ã«ãã
ã¹ã¿ãã³ãçµåãããŠãªãéžæç殺现èæ§èçœè€
åäœã ãåŒäžãAbã¯æè «çIgGå ç«ã°ãããªã³ãŸã
ã¯ãã®ãã©ã°ã¡ã³ããè¡šããAbã¯ãã®ååŠæ§é
äžã®ã¢ããåºã§çµåããŠãããNCSã¯ããªã«ã«
ããã¹ã¿ãã³ãè¡šããNCSã¯ãã®ååŠæ§é äžã®
ã¢ããåºã§çµåããŠãããã¯ïœâããšãã¬ã³åº
ãŸãã¯ããªã¡ãã¬ã³åºããïœã¯ïŒãŸãã¯ïŒãè¡š
ããã¯ã€ãªãŠååãè¡šãããïœãïŒã®ãšãã¯
æè «çIgGå ç«ã°ãããªã³ãŸãã¯ãã®ãã©ã°ã¡ã³
ãã®ååŠæ§é ãå æ¥æããããªãŒã«åºã«ç±æ¥ãã
ïœãïŒã®ãšãã¯å°å ¥ãããææ©åºãå«æããããª
ãŒã«åºã«ç±æ¥ãããïœã¯ïŒãïŒã®æŽæ°ãè¡šããã ïŒ äžèšåŒãã ãåŒäžãAbã¯æè «çIgGå ç«ã°ãããªã³ãŸã
ã¯ãã®ãã©ã°ã¡ã³ããè¡šããAbã¯ãã®ååŠæ§é
äžã®ã¢ããåºã§çµåããŠãããïœã¯ïŒãŸãã¯ïŒã
è¡šããã¯ã€ãªãŠååãè¡šãããïœãïŒã®ãšã
ã¯æè «çIgGå ç«ã°ãããªã³ãŸãã¯ãã®ãã©ã°ã¡
ã³ãã®ååŠæ§é ãå æ¥æããããªãŒã«åºã«ç±æ¥
ããïœãïŒã®ãšãã¯å°å ¥ãããææ©åºãå«æãã
ããªãŒã«åºã«ç±æ¥ãããn1ã¯ïŒãïŒã®æŽæ°ãè¡š
ããã ã§è¡šãããçºçãŸãã¯å°å ¥ãããããªãŒã«åºãæ
ããæè «çIgGå ç«ã°ãããªã³ãŸãã¯ãã®ãã©ã°
ã¡ã³ããšäžèšåŒãã ãåŒäžãNCSã¯ããªã«ã«ããã¹ã¿ãã³ãè¡šãã
NCSã¯ãã®ååŠæ§é äžã®ã¢ããåºã§çµåããŠã
ããã¯ïœâããšãã¬ã³åºãŸãã¯ããªã¡ãã¬ã³åº
ãè¡šãã ã§è¡šãããå°å ¥ããããã¬ã€ããåºãæããããª
ã«ã«ããã¹ã¿ãã³ãåå¿ãããããšãç¹åŸŽãšãã äžèšåŒãã ãåŒäžãïœã¯ïŒãïŒã®æŽæ°ãè¡šããAbãïœã
ãNCSããã³ïŒžã¯äžèšå®çŸ©ã®ãšããã ã§è¡šãããéžæç殺现èæ§èçœè€åäœã®è£œé æ¹
æ³ã[Scope of Claims] 1. A selective cell-killing protein complex formed by binding an anti-tumor IgG immunoglobulin or a fragment thereof to neocarzinostatin, represented by the following formula []. [wherein Ab represents an antitumor IgG immunoglobulin or a fragment thereof, and Ab is bonded through an amino group in its chemical structure. NCS stands for neocarzinostatin, and NCS is attached through an amino group in its chemical structure. X represents an m-phenylene group or a trimethylene group, and m represents 0 or 1. S represents a sulfur atom, and when m is 0, S is derived from a thiol group originally contained in the chemical structure of the antitumor IgG immunoglobulin or its fragment;
When m is 1, it originates from a thiol group contained in the introduced organic group. n represents an integer of 1 to 5. ] 2 The following formula [] [wherein Ab represents an antitumor IgG immunoglobulin or a fragment thereof, and Ab is bonded through an amino group in its chemical structure. m represents 0 or 1. S represents a sulfur atom, but when m is 0, S
m is derived from a thiol group originally contained in the chemical structure of the antitumor IgG immunoglobulin or its fragment, and when m is 1, it is derived from a thiol group contained in the introduced organic group. n1 represents an integer from 1 to 5. ] An anti-tumor IgG immunoglobulin having a generated or introduced thiol group represented by or a fragment thereof and the following formula [] [In the formula, NCS represents neocarzinostatin,
NCS is bonded through amino groups in its chemical structure. X represents an m-phenylene group or a trimethylene group] The following formula [] is characterized by reacting neocarzinostatin having an introduced maleimide group represented by the following formula [] [In the formula, n represents an integer of 1 to 5, Ab, m,
S, NCS and X are as defined above.] A method for producing a selective cell-killing protein complex.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57151754A JPS5942323A (en) | 1982-09-02 | 1982-09-02 | Conjugated protein killing selectively cell and its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57151754A JPS5942323A (en) | 1982-09-02 | 1982-09-02 | Conjugated protein killing selectively cell and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5942323A JPS5942323A (en) | 1984-03-08 |
JPH0428720B2 true JPH0428720B2 (en) | 1992-05-15 |
Family
ID=15525559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57151754A Granted JPS5942323A (en) | 1982-09-02 | 1982-09-02 | Conjugated protein killing selectively cell and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5942323A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2564839B1 (en) * | 1984-05-23 | 1986-11-14 | Sanofi Sa | CONJUGATES COMBINING BY COVALENT BINDING A MONOVALENT CARBOXYLIC IONOPHORE AND A MACROMOLECULE AND THEIR USE AS POTENTIALIZERS OF IMMUNOTOXINS |
US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
-
1982
- 1982-09-02 JP JP57151754A patent/JPS5942323A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5942323A (en) | 1984-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0023401B1 (en) | Antitumor protein hybrid and process for the preparation thereof | |
EP0031999B1 (en) | Antitumor protein hybrid and process for the preparation thereof | |
JP2942356B2 (en) | Therapeutic complexes containing toxins and drugs | |
JPH021129B2 (en) | ||
US4507234A (en) | Conjugate having cytotoxicity and process for the preparation thereof | |
JP3633613B2 (en) | Immunotoxins against c-erbB-2 (HER-2 / neu) associated with surface antigens | |
JPH021128B2 (en) | ||
JPS61500789A (en) | Monoclonal anti-human breast cancer antibody | |
EP0279862A1 (en) | Cytocidal antibody complex and process for its preparation | |
JPH0133448B2 (en) | ||
PL172837B1 (en) | Pharmaceutic preparation containing thioether conjugates | |
IE67448B1 (en) | Cross-linked antibodies and processes for their preparation | |
JPH0259128B2 (en) | ||
KR860001149B1 (en) | Process for preparing immunoglobulin conjugates | |
US6509451B1 (en) | Cross-linked antibodies and processes for their preparation | |
EP0017507B1 (en) | Antitumor protein hybrid and process for the preparation thereof | |
WO2022152289A1 (en) | An engineered antibody and antibody-drug conjugates comprisign same | |
JPH0641423B2 (en) | Cytotoxic drug composition and cytotoxic drug kit | |
JPH0428720B2 (en) | ||
US5151266A (en) | Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies | |
EP2049570B1 (en) | Purification of a bivalently active antibody using a non-chromatographic method | |
US4767621A (en) | Drugs comprising in association at least one immunotoxin and at least one monovalent carboxylic ionophore | |
JPS59134734A (en) | Cytocidal modified immunoglobulin and its preparation | |
HAISMA et al. | A monoclonal antibody against human β-glucuronidase for application in antibody-directed enzyme prodrug therapy | |
JPS58167519A (en) | Cytotoxic complex and preparation thereof |